← Oncology Approval Tracker

FDA DECISION ·

Keytruda / Keytruda Qlex + Padcev

pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, each with enfortumab vedotin-ejfv · Merck / Astellas

FDA approvalNew or expanded indicationBladder cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with muscle-invasive bladder cancer who are candidates for cystectomy. The combination is given before surgery and after cystectomy, expanding the previous cisplatin-ineligible use.

LAMPGEN ANALYSIS

Why it matters

This extends the perioperative option to cisplatin-eligible patients. The two treatment phases make the surgery milestone integral to interpreting trial execution and outcomes.

What research teams should watch

Track the transition from neoadjuvant dosing to cystectomy and the return to adjuvant treatment. Capture surgery delays, safety events and the distinction between clinical and pathologic assessments.

Clinical operations takeaway

Agree on who tracks surgery and treatment milestones across the teams involved. Give delays a defined escalation path and document who decides when the next study activity can proceed.

Scope CTM ownership across study milestones

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

Perioperative muscle-invasive bladder cancer

PRIMARY RECORDS

Sources